Wohlbold Teddy John, Hirsh Ariana, Krammer Florian
Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vaccine. 2015 Feb 25;33(9):1102-6. doi: 10.1016/j.vaccine.2015.01.026. Epub 2015 Jan 17.
Three human cases of H10N8 viruses were reported in China in late 2013 and early 2014, two of which were fatal. This was the first time the H10N8 subtype has been detected in humans and no vaccine candidates or antibody therapy has been developed for these viruses so far. We developed an H10N8 vaccine candidate virus based on A/Jiangxi-Donghu/346/13 that can also be used in a murine challenge model for vaccine and monoclonal antibody research. The vaccine virus is a 6:2 re-assortant virus expressing the surface glycoproteins of A/Jiangxi-Donghu/346/13 on an A/Puerto Rico/8/34 backbone. Vaccination with inactivated challenge virus or recombinant hemagglutinin or neuraminidase derived from this strain protected mice from viral challenge.
2013年末至2014年初,中国报告了3例H10N8病毒感染人类的病例,其中2例死亡。这是首次在人类中检测到H10N8亚型病毒,目前尚未开发出针对这些病毒的候选疫苗或抗体疗法。我们基于A/江西-东湖/346/13毒株研发了一种H10N8候选疫苗病毒,该病毒也可用于疫苗和单克隆抗体研究的小鼠攻毒模型。该疫苗病毒是一种6:2重配病毒,在A/波多黎各/8/34骨架上表达A/江西-东湖/346/13的表面糖蛋白。用该毒株的灭活攻毒病毒或重组血凝素或神经氨酸酶进行疫苗接种可保护小鼠免受病毒攻击。